Ernexa Therapeutics
$6.30
364
+$0.15+2.44% Monday 20:00
Statistics
Day High
6.75
Day Low
6.3
52W High
71.5
52W Low
3.18
Volume
19,763
Avg. Volume
-
Mkt Cap
0
P/E Ratio
0.01
Dividend Yield
-
Dividend
-
Upcoming
Earnings
17AugExpected
Expected EPS
-3.3
Actual EPS
N/A
Financials
-31,888.24%Profit Margin
Unprofitable68,000Revenue
-21.68MNet Income
Analyst Ratings
30.00Average Price Target
The highest estimate is 30.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow ERNA. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
ARK Innovation
ARKK
Mkt Cap0
Invesco QQQ Trust Series 1
QQQ
Mkt Cap0
Vanguard Information Technology
VGT
Mkt Cap0
iShares Expanded Tech-Software Sector
IGV
Mkt Cap0
First Trust Dow Jones Internet Index Fund
FDN
Mkt Cap0
ARK Next Generation Internet
ARKW
Mkt Cap0
State Street SPDR FactSet Innovative Technology
XITK
Mkt Cap0
ROBO Global Robotics and Automation Index
ROBO
Mkt Cap0
First Trust Cloud Computing
SKYY
Mkt Cap0
About
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
Show more...
CEO
Mr. Sanjeev Luther
Employees
6
Country
United States
ISIN
US1140824079
Listings
0 Comments
Share your thoughts
FAQ
What is Ernexa Therapeutics stock price today?▼
The current price of ERNA is $6.30 USD — it has increased by +2.44% in the past 24 hours. Watch Ernexa Therapeutics stock price performance more closely on the chart.
What is Ernexa Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ernexa Therapeutics stocks are traded under the ticker ERNA.
Is Ernexa Therapeutics stock price growing?▼
ERNA stock has fallen by -7.35% compared to the previous week, the month change is a -53.78% fall, over the last year Ernexa Therapeutics has showed a -89.46% decrease.
When is the next Ernexa Therapeutics earnings date?▼
Ernexa Therapeutics is going to release the next earnings report on August 17, 2026.
What were Ernexa Therapeutics earnings last quarter?▼
ERNA earnings for the last quarter are -6.95 USD per share, whereas the estimation was -1.95 USD resulting in a -256.41% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ernexa Therapeutics revenue for the last year?▼
Ernexa Therapeutics revenue for the last year amounts to 68,000 USD.
What is Ernexa Therapeutics net income for the last year?▼
ERNA net income for the last year is -21.68M USD.
How many employees does Ernexa Therapeutics have?▼
As of June 16, 2026, the company has 6 employees.
In which sector is Ernexa Therapeutics located?▼
Ernexa Therapeutics operates in the Health & Wellness sector.
When did Ernexa Therapeutics complete a stock split?▼
The last stock split for Ernexa Therapeutics was on May 04, 2026 with a ratio of 1:25.
Where is Ernexa Therapeutics headquartered?▼
Ernexa Therapeutics is headquartered in Cambridge, United States.